Rhythm Biosciences Limited · ASX:RHY

Rhythm Biosciences — Shareholder Meeting (November 2018)

14 slides from Rhythm Biosciences's shareholder meeting presentation, Nov 26, 2018

  1. Slide 1: Rhythm Biosciences

    Rhythm Biosciences (ASX: RHY) A Medical Diagnostics Technology Company Mission: To reduce the impact of colorectal cancer globally through improved diagnosis November 2018 © Rhythm Biosciences Ltd. All rights reserved.

  2. Slide 2: Disclaimer

    Disclaimer • This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or unde

  3. Slide 3: Colorectal cancer is the world's 2nd biggest cancer killer

    Colorectal cancer is the worlds 2nd biggest cancer killer Early Intervention Saves Lives Regular screening is key to picking up cancers early CONFIDENTIAL © Rhythm Biosciences Ltd. All rights reserved. 3

  4. Slide 4: Addressable market of 250 million people in EU, USA & AU

    Addressable market of 250 million people in EU, USA & AU Despite faecal & colonoscopy tests, 130+ million remain totally unscreened Blood testing has the potential to sharply increase participation CONFIDENTIAL 4 © Rhythm Biosciences Ltd. All rights reserved.

  5. Slide 5: What is ColoSTAT

    What is ColoSTAT® Rhythm Biosciences is developing ColoSTAT for market a simple blood test to accurately detect colorectal cancer Blood tests are the preferred screening method in over 83% of the currently unscreened population Over 13 years of development at CSIRO - Australia's preeminent research

  6. Slide 6: ColoSTAT Published Performance

    ColoSTAT® Published Performance ColoSTAT® 73% sensitivity for all colorectal cancer at 95% specificity 58% sensitivity for early (Stage I) colorectal cancer at 95% specificity Fung et al. Blood-based protein biomarker panel for the detection of colorectal cancer. PLoS One (2015) 10 3. FIT (Faecal Im

  7. Slide 7: Key Milestones Achieved to Date

    Key Milestones Achieved to Date ✓ IPO listing Dec 2017 ✓ Strong management & board ✓ Strong global patent position ✓ Reagent development on track for 2018 ✓ Kit development & optimisation on track for 2019 ✓ Last two Studies (6 & 7) on track for 2019 ✓ Ongoing CSIRO relationship remains strong ✓ Foc

  8. Slide 8: Key Drivers

    Key Drivers ✓250 million addressable market in screening alone ✓Globally bowel cancer kills 700,000+ people pa ✓1.4 million new cases of colorectal cancer annually ✓2nd most prevalent cancer in Europe, US & Aust ✓$6bn+ global screening market alone ✓$33bn global economic burden Strategic Objective:

  9. Slide 9: Competitive landscape in colorectal screening

    Competitive landscape in colorectal screening High cost Low cost CONFIDENTIAL © Rhythm Biosciences Ltd. All rights reserved. 9

  10. Slide 10: Commercial Opportunities: Government

    Commercial Opportunities: Government ✓ Objective to replace the Faecal Immunochemical Test (FIT) as global screening test of choice ✓ For those who don’t do FIT tests (up to 50% untested) ✓ An additional test for FIT-positive patients to determine need for colonoscopy & reduce unnecessary/expensive

  11. Slide 11: Commercial Opportunities: Non-Government

    Commercial Opportunities: Non-Government ColoSTAT® has the ability to be marketed across multiple channels simultaneously including: ✓ Global IVD/Pharma Companies ✓ Global Private Health Funds (redn. in unnecessary colonoscopy spend) ✓ Global Pathology Clinics (adapts easily to existing ELISA infras

  12. Slide 12: Key Milestones - 2019

    Key Milestones - 2019 ✓ IVD kit development on track for completion in 2019 ✓ Study 6 on track for completion in 2019 ✓ Study 7 Clinical Trial on track for completion in 2019 ✓ First patient to be recruited by Q1 2019 for Study 7 ✓ ISO 13485 quality certification to be achieved in 2019 ✓ Regulatory

  13. Slide 13: Summary

    Summary • An addressable screening market of 250m people • Multi-billion dollar opportunity in screening alone • Product that costs less, simple to use & more accurate than the current faecal test • Experienced board & executive team • Patents filed in key global jurisdictions • Potential to expand

  14. Slide 14: Thank you

    Thank you For more information visit rhythmbiosciences.com © Rhythm Biosciences Ltd. All rights reserved.

Rhythm Biosciences — Shareholder Meeting (November 2018) on 6ix